US › Healthcare

Plus Therapeutics Inc (PSTV)

US · Healthcare · Biotechnology

$3.96+12.50%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$1.0M
Revenue YoY
-2.9%
Net profit
$-6.9M
Profit YoY
+60.1%
EPS
$-1.05
EPS estimate
$-0.87
Net margin
-675.7%

EPS came in at -1.05 against a street estimate of -0.87 — a miss of 20.7%.

Key statistics

Market cap
$26.6M
P/E
0.2
Forward P/E
1.0
P/B
2.23
Book value
$1.74
EPS (TTM)
$21.56
52-week high
$23.50
52-week low
$2.90
50-day MA
$4.66
200-day MA
$8.43
Beta
1.40

Analyst view

Analysts rate Plus Therapeutics Inc a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $36.00.

Shareholding

Insiders
1.84%
Institutions
13.40%

Largest institutional holders

FundStake
Vanguard Group Inc1.32%
Geode Capital Management, LLC1.17%
BlackRock Inc1.03%
State Street Corp0.27%
Northern Trust Corp0.17%
XTX Topco Ltd0.07%
Citigroup Inc0.05%
UBS Group AG0.05%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Plus Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.